<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980304</url>
  </required_header>
  <id_info>
    <org_study_id>ML22515</org_study_id>
    <nct_id>NCT00980304</nct_id>
  </id_info>
  <brief_title>R Retreatment in 1st Relapsed DLBCL</brief_title>
  <official_title>A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients
      after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to
      receive 3 cycles of RICE as salvage therapy.

      After treatment each patient should be followed up for 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>1</number_of_arms>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>Rituximab in combination with ICE as salvage therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab in combination with ICE as salvage therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed DLBCL patients having received 6 - 8 cycles of RCHOP-like chemotherapy as 1st
             line induction treatment.

          2. Disease relapsed no earlier than 6 months after prior induction treatment.

          3. Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction
             therapy)

          4. ECOG performance status of 0, 1 or 2 at time of inclusion (see Appendix IV )

          5. Known IPI at time of diagnosis (prior to induction therapy)

          6. Age ≥18 years and &lt;65 y

          7. Life expectancy of &gt; 3 months

          8. Be willing and able to comply with the protocol for the duration of the study

          9. Agree to use effective contraception for the entire treatment period and during the 12
             months thereafter

         10. Patient's written informed consent

        Exclusion Criteria:

          1. More than one prior chemoimmunotherapy regimen.

          2. Histologies other than DLBCL according to the WHO/REAL classification

          3. History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the
             skin, surgically treated malignant melanoma or carcinoma in situ of the cervix within
             the last 5 years.

          4. Major surgery, other than diagnostic surgery, within the last 4 weeks.

          5. Evidence of CNS involvement patients

          6. Unacceptable hematologic status at baseline prior to study start below any of the
             values listed: WBC: &lt;3 x 109/L; absolute neutrophil count (segmented + bands) &lt;1.5 x
             109/L; platelets: &lt;100 x109/L

          7. Abnormal liver function tests prior to study start above any of the values listed:
             serum bilirubin &gt;2 mg/dL (30 mmol/L); ALAT or ASAT &gt;2.5 x upper limit of normal range;
             or Abnormal renal function (serum creatinine &gt; 150 μmol/L ).

          8. HIV-positive patients.

          9. Contraindication to the investigational medication

         10. Active viral hepatitis, specifically HBV or HCV infection

         11. Serious underlying medical conditions, (e.g. ongoing infection, uncontrolled diabetes
             mellitus, severe cardiac dysfunction or angina, gastric ulcers, active autoimmune
             disease)

         12. Life expectancy &lt; 3 months

         13. Treatment within a clinical trial within 30 days prior to trial entry

         14. Women who are breast feeding, are not using effective contraception, are pregnant

         15. Patients under tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shen, Zhixiang / Professor</name_title>
    <organization>Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine</organization>
  </responsible_party>
  <keyword>Diffuse large B cell lymphomas</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

